Abstract

BackgroundThe aim of this study was to observe the effectiveness of botulinum toxin type A (BTA) in the treatment of intermittent exotropia (IXT) in children compared with strabismus surgery.MethodsOne hundred forty-four children with a clear diagnosis of IXT and an indication for surgery were eligible for inclusion. Subjects were divided into two groups based on parental decision: the BTA injection group (injection group) or the conventional surgery group (surgery group). All cases were followed up for 6 months. The primary outcome was a comparison of the success rate (deviation between − 10 and + 10 PD) between the two groups at 6 months after the initial treatment. Secondary outcomes included change in deviation, visual function, and post-surgical complications.ResultsSeventy-two patients were enrolled in each group. At 6-month follow-up, there was no significant difference in the success rate between the injection and surgery groups (52.8% vs 66.7%, P = 0.13; postoperative deviation − 12.22 ± 10.80 PD vs − 9.17 ± 10.30 PD, P = 0.09). The binocular Visual function, except for near stereoacuity, improved after treatment in both groups, while the fusion recovery rate was higher in the surgical group (68.1% vs 95.8%, P < 0.001). Transient complications in the injection group included diplopia, ptosis, and subconjunctival hemorrhage, whereas subconjunctival hemorrhage, conjunctival edema, foreign body sensation, pain, and diplopia were seen in the surgical group. The complications of BTA were relatively mild.ConclusionsBTA is as effective as surgery in the treatment of IXT in children, but the recovery of the fusion is lower than surgery.Trial registrationThe study has completed the clinical registration on (ChiCTR-INR-17013777).

Highlights

  • The aim of this study was to observe the effectiveness of botulinum toxin type A (BTA) in the treatment of intermittent exotropia (IXT) in children compared with strabismus surgery

  • Botulinum toxin type A (BTA) is a neurotoxin synthesized by Clostridium botulinum and was first applied in the treatment of strabismus by Scott [1] in 1973

  • Some of the advantages of BTA injection include not affecting the anatomical position of the extraocular muscles (EOM), maintaining longterm physiological function, reproducibility, simplicity of operation, and few side effects

Read more

Summary

Introduction

The aim of this study was to observe the effectiveness of botulinum toxin type A (BTA) in the treatment of intermittent exotropia (IXT) in children compared with strabismus surgery. Intermittent exotropia (IXT) is one of the common eye diseases among children. Botulinum toxin type A (BTA) is a neurotoxin synthesized by Clostridium botulinum and was first applied in the treatment of strabismus by Scott [1] in 1973. The rationale for the elimination of strabismus by BTA is to temporarily reduce the tone of the extraocular muscles (EOM) by chemical denervation, inducing a specific EOM paralysis. During the restoration of equilibrium of the extraocular muscles, binocular vision is gradually restored and leads to the reconstruction of the alignment position of the eyes, resulting in the treatment of strabismus [3]. Some of the advantages of BTA injection include not affecting the anatomical position of the EOM, maintaining longterm physiological function, reproducibility, simplicity of operation, and few side effects

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call